Coldstream Capital Management Inc. Grows Stock Position in Organon & Co. $OGN

Coldstream Capital Management Inc. lifted its position in Organon & Co. (NYSE:OGN) by 61.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,686 shares of the company’s stock after acquiring an additional 8,644 shares during the period. Coldstream Capital Management Inc.’s holdings in Organon & Co. were worth $220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Hanson & Doremus Investment Management purchased a new position in Organon & Co. in the 2nd quarter valued at $26,000. Hantz Financial Services Inc. lifted its stake in shares of Organon & Co. by 293.8% in the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after buying an additional 1,995 shares in the last quarter. Ransom Advisory Ltd acquired a new position in Organon & Co. during the first quarter worth about $32,000. SouthState Corp boosted its position in Organon & Co. by 1,857.0% during the second quarter. SouthState Corp now owns 3,914 shares of the company’s stock worth $38,000 after acquiring an additional 3,714 shares during the last quarter. Finally, Allworth Financial LP grew its stake in Organon & Co. by 65.9% during the 2nd quarter. Allworth Financial LP now owns 4,501 shares of the company’s stock valued at $44,000 after acquiring an additional 1,788 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Morgan Stanley cut their price objective on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 11th. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. reduced their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Organon & Co. presently has a consensus rating of “Hold” and an average price target of $12.50.

Organon & Co. Stock Performance

Organon & Co. stock opened at $7.72 on Friday. The firm has a 50 day simple moving average of $8.59 and a 200-day simple moving average of $9.27. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 4.02, a price-to-earnings-growth ratio of 1.65 and a beta of 0.59. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20. Organon & Co. has a 1-year low of $6.18 and a 1-year high of $17.23.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the company earned $1.38 EPS. Organon & Co. has set its FY 2025 guidance at EPS. On average, analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th will be given a $0.02 dividend. The ex-dividend date is Thursday, November 20th. This represents a $0.08 dividend on an annualized basis and a yield of 1.0%. Organon & Co.’s payout ratio is currently 4.17%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.